CA
NZ
UK
AU
IND
US
Gregory Babcock, Vice President and Chief Accounting Officer of Talos Energy Inc., filed a Form 4 on August 31, 2026, reporting the sale of 61,307 shares of common stock on August 27, 2026.
A Form 4 filed on August 31, 2026, with the U.S. Securities and Exchange Commission disclosed that Olivier Le Peuch, Chief Executive Officer and Director of SLB Limited/NV (NYSE:SLB), sold 5,000 shares of common stock on August 31, 2026, pursuant to a pre-established Rule …
Patricia Y. Grech, Senior Vice President and Chief Accounting Officer of Qualcomm Inc/DE (NASDAQ:QCOM), filed a Form 4 on August 31, 2026, disclosing the sale of 208 shares of common stock held indirectly through a family trust.
Marcus J. Moeltner, CFO and SVP of Finance at Rayonier Advanced Materials Inc., was granted 30,386 Performance-Based Leveraged Performance Units on August 27, 2026, according to a beneficial ownership statement filed with the SEC on August 31, 2026.
A Form 4 filed on August 28, 2026 disclosed that Marie Manon Lise Gingras, Vice President of Human Resources at Rayonier Advanced Materials Inc., received a grant of Performance-Based Leveraged Performance Units on August 27, 2026.
A Form 4 filed on August 28, 2026, with the SEC discloses that Christopher W. Sittard, Vice President of Sourcing at Rayonier Advanced Materials Inc. (NYSE:RYAM), was granted 2,889 Performance-Based Leveraged Performance Units on August 27, 2026.
Jean-Briac Perrette, President and CEO of Global Streaming at Warner Bros. Discovery, Inc., filed a Form 4 on August 31, 2026, reporting the sale of Series A Common Stock on August 27, 2026.
Robert I. Blum, President and CEO of Cytokinetics Inc., filed a Form 4 on August 31, 2026, disclosing the exercise of a stock option and same-day sale of 7,500 shares of common stock pursuant to a Rule 10b5-1 plan.
A statement of changes in beneficial ownership was filed on August 31, 2026, disclosing that Ernst W. Bruderer, a director of CoastalSouth Bancshares, Inc. (NYSE:COSO), sold 2,000 shares of common stock on that same date.
Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc (NASDAQ:CYTK), filed a Form 4 on August 31, 2026, disclosing the exercise of 10,000 stock options and the same-day sale of 10,000 shares of common stock.
Please wait processing your request...